

Filed: March 18, 2016

Filed on behalf of:

**Ranbaxy Inc.**

By: Joseph M. Reisman

Carol Pitzel Cruz

Kerry S. Taylor

KNOBBE, MARTENS, OLSON & BEAR, LLP

2040 Main Street, 14th Floor

Irvine, CA 92614

Tel.: (949) 760-0404

Fax: (949) 760-9502

E-mail: BoxRanbaxy332@knobbe.com

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

**RANBAXY INC.,**

Petitioner

v.

**JAZZ PHARMACEUTICALS, INC., and  
JAZZ PHARMACEUTICALS IRELAND LTD.,**

Patent Owners

---

Case No. **TBD**

Patent 9,050,302

---

**PETITIONER'S CORRECTED EXHIBIT LIST**

Pursuant to 37 C.F.R. § 42.63(e), Petitioner hereby provides a corrected list of its exhibits to include Exhibit 1002.

Exhibit No.	Description
Ex. 1001	U.S. Patent No. 9,050,302, issued June 9, 2015
Ex. 1002	Declaration of David P. Rotella, Ph.D. (“Rotella Declaration”)
Ex. 1003	Maitre, M., The $\gamma$ -Hydroxybutyrate Signalling System in Brain Organization and Functional Implications, <i>Progress in Neurobiology</i> , Vol. 51, pp. 337-361 (1997) (“Maitre”)
Ex. 1004	Okun, M., GHB: An Important Pharmacologic and Clinical Update, <i>J. Pharm. Pharmaceut. Sci.</i> , Vol. 4(2), pp. 167-175 (2001) (“Okun”)
Ex. 1005	The Xyrem® Package Insert entry in the Physician’s Desk Reference Edition, pp. 1688-1692, (2007) (“the Xyrem® PI”)
Ex. 1006	Xyrem® Titration Schedule published in 2008 (“the Xyrem®-TS”)
Ex. 1007	Waszkielewicz, et al., $\gamma$ -Hydroxybutyric acid (GHB) and its Chemical Modifications: A Review of the GHBergic System, <i>Pol. J. Pharmacol.</i> , Vol. 56, pp. 43-49 (2004) (“Waszkielewicz”)
Ex. 1008	Broughton, R., The Treatment of Narcolepsy-Cataplexy with Nocturnal Gamma-Hydroxybutyrate, <i>Can. J. Neurol. Sci.</i> , Vol. 6(1), pp. 1-6 (1979)
Ex. 1009	Broughton, R., Effects of Nocturnal Gamma-Hydroxybutyrate on Sleep/Waking Patterns in Narcolepsy-Cataplexy; <i>Can. J. Neurol. Sci.</i> , Vol. 7(1), pp. 23-31 (1980)

Exhibit No.	Description
Ex. 1010	Cash, C. D., Gammahydroxybutyrate: An Overview of the Pros and Cons for it Being a Neurotransmitter And/Or a Useful Therapeutic Agent, <i>Neurosci. Biobehavioral Rev.</i> , Vol. 18(2), pp. 291-304 (1994)
Ex. 1011	Mamelak, et al., Treatment of Narcolepsy with Hydroxybutyrate. A Review of Clinical and Sleep Laboratory Findings, <i>Sleep</i> , Vol. 9(1), pp. 285-289 (1986)
Ex. 1012	Scharf, et al., The Effects and Effectiveness of $\gamma$ -Hydroxybutyrate in Patients with Narcolepsy; <i>J. Clin. Psychiatry</i> , Vol. 46, pp. 222-225 (1985)
Ex. 1013	Scharf, et al., Pharmacokinetics of Gammahydroxybutyrate (GHB) in Narcoleptic Patients, <i>Sleep</i> , Vol. 21(5), pp. 507-514 (1998)
Ex. 1014	Bernasconi, et al., Experimental Absence Seizures: Potential Role of $\gamma$ -Hydroxybutyric Acid and GABAB Receptors, <i>J. Neural Transm.</i> , Vol. 35, pp. 155-177 (1992)
Ex. 1015	Hechler, et al., $\gamma$ -Hydroxybutyrate Conversion into GABA Induces Displacement of GABAB Binding that is Blocked by Valproate and Ethosuximide, <i>JPET</i> , Vol. 281(2), pp. 753-760 (1997)
Ex. 1016	Kaufman, et al., Evidence for the Participation of a Cytosolic NADP <sup>+</sup> -Dependent Oxidoreductase in the Catabolism of Gamma-Hydroxybutyrate In Vivo, <i>J. Neurochem.</i> , Vol. 48(6), pp. 1935-1941 (1987)
Ex. 1017	Kaufman, et al., An Overview of $\gamma$ -Hydroxybutyrate Catabolism: The Role of the Cytosolic NADP <sup>+</sup> -Dependent Oxidoreductase EC 1.1.1.19 and a Mitochondrial Hydroxyacid-Oxoacid Transhydrogenase in the Initial, Rate-Limiting Step in This Pathway, <i>Neurochem. Res.</i> , Vol. 16(9), pp. 965-974 (1991)

Exhibit No.	Description
Ex. 1018	Knerr, et al., Therapeutic Concepts in Succinate Semialdehyde Dehydrogenase (SSADH; ALDH5a1) Deficiency ( $\gamma$ -Hydroxybutyric Aciduria). Hypotheses Evolved From 25 Years of Patient Evaluation, Studies in <i>Aldh5a1</i> <sup>-/-</sup> Mice and Characterization of $\gamma$ -Hydroxybutyric Acid Pharmacology, <i>J. Inherit. Metab. Dis.</i> , Vol. 30, pp. 279-294 (2007)
Ex. 1019	Löscher, W., Valproate: A Reappraisal of Its Pharmacodynamic Properties and Mechanisms of Action, <i>Progress in Neurobiol.</i> , Vol. 58, pp. 31-59 (1999)
Ex. 1020	Löscher, W., Basic Pharmacology of Valproate: A Review After 35 Years of Clinical Use for the Treatment of Epilepsy, <i>CNS Drugs</i> , Vol. 16(1), pp. 669-694 (2002)
Ex. 1021	Vayer, et al., 3'-5' Cyclic-Guanosine Monophosphate Increase in Rat Brain Hippocampus after Gamma-Hydroxybutyrate Administration. Prevention by Valproate and Naloxone, <i>Life Sciences</i> , Vol. 41, pp. 605-610 (1987)
Ex. 1022	Vayer, et al., Is the Anticonvulsant Mechanism of Valproate Linked to its Interaction with the Cerebral $\gamma$ -Hydroxybutyrate System? <i>TIPS</i> , Vol. 9, pp. 127-129 (1988)
Ex. 1023	Weiss, et al., Gamma-hydroxybutyrate (GHB) and Topiramate – Clinically Relevant Drug Interaction Suggested by a Case of Coma and Increased Plasma GHB Concentration, <i>Eur. J. Clin. Pharmacol.</i> , Vol. 69, pp. 1193-94 (2013)
Ex. 1024	Cagnin, et al., $\gamma$ -Hydroxybutyric Acid-Induced Psychosis Seizures, <i>Epilepsy and Behav.</i> , Vol. 21, pp. 203-205 (2011)

Exhibit No.	Description
Ex. 1025	Morris, et al., Overview of the Proton-coupled MCT (SLC16A) Family of Transporters: Characterization, Function and Role in the Transport of the Drug of Abuse $\gamma$ -Hydroxybutyric Acid, <i>AAPS J.</i> , 10(2), pp.311-321 (2008) (“Morris I”)
Ex. 1026	Morris, et al., Monocarboxylate Transporter with Osmotic Diuresis Increases $\gamma$ -Hydroxybutyrate Renal Elimination in Humans: A Proof-of-Concept Study, <i>J. Clin. Tox.</i> , 1(2), 1000105, pp. 1-4 (2011) (“Morris II”)
Ex. 1027	Bhattacharya, et al., GHB ( $\gamma$ -Hydroxybutyrate) Carrier-Mediated Transport across the Blood-Brain Barrier, <i>J. Pharm. &amp; Experimental Therapeutics</i> , 311(1), pp. 92-98 (2004)
Ex. 1028	Curriculum Vitae for David Rotella, Ph.D.
Ex. 1029	Depakene® Package Insert dated October 2011 (“Depakene® Package Insert”)
Ex. 1030	Draft FDA Guidance dated February 2012 (“FDA Guidance”)
Ex. 1031	Lamictal® Package Insert dated November 29, 2011 (“Lamictal® Package Insert”)
Ex. 1032	U.S. Patent No. 8,772,306 Patent File History, Supplemental Amendment and Response filed November 13, 2013
Ex. 1033	U.S. Patent No. 8,772,306, issued July 8, 2014
Ex. 1034	Petition for <i>Inter Partes Review</i> of U.S. Patent No. 8,772,306, <i>Par Pharmaceutical, Inc. v. Jazz Pharmaceuticals, Inc.</i> , IPR2016-00002
Ex. 1035	Declaration of John W. Winkelman, <i>Par Pharmaceutical, Inc. v. Jazz Pharmaceuticals, Inc.</i> , IPR2016-00002

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.